DE202007000949U1 - Oral composition, useful for treating e.g. attention deficit disorder, comprises fish oil comprising omega-3- and/or omega-6-fatty acid, magnesium and zinc, optionally carriers and further auxiliary materials - Google Patents

Oral composition, useful for treating e.g. attention deficit disorder, comprises fish oil comprising omega-3- and/or omega-6-fatty acid, magnesium and zinc, optionally carriers and further auxiliary materials Download PDF

Info

Publication number
DE202007000949U1
DE202007000949U1 DE202007000949U DE202007000949U DE202007000949U1 DE 202007000949 U1 DE202007000949 U1 DE 202007000949U1 DE 202007000949 U DE202007000949 U DE 202007000949U DE 202007000949 U DE202007000949 U DE 202007000949U DE 202007000949 U1 DE202007000949 U1 DE 202007000949U1
Authority
DE
Germany
Prior art keywords
omega
fatty acid
zinc
magnesium
fish oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202007000949U
Other languages
German (de)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KRANICH PHARMA GMBH, DE
Original Assignee
ALFRED ADAM
HEUSCHEN KLAUS WERNER
VOGEL LUKAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALFRED ADAM, HEUSCHEN KLAUS WERNER, VOGEL LUKAS filed Critical ALFRED ADAM
Priority to DE202007000949U priority Critical patent/DE202007000949U1/en
Publication of DE202007000949U1 publication Critical patent/DE202007000949U1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oral composition comprises fish oil comprising omega-3-fatty acid and/or omega-6-fatty acid, micro nutrients such as magnesium and zinc, optionally carriers and further auxiliary materials. ACTIVITY : Nootropic; Tranquilizer; Antidepressant; Neuroprotective. No biological data given. MECHANISM OF ACTION : None given.
DE202007000949U 2007-01-23 2007-01-23 Oral composition, useful for treating e.g. attention deficit disorder, comprises fish oil comprising omega-3- and/or omega-6-fatty acid, magnesium and zinc, optionally carriers and further auxiliary materials Expired - Lifetime DE202007000949U1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE202007000949U DE202007000949U1 (en) 2007-01-23 2007-01-23 Oral composition, useful for treating e.g. attention deficit disorder, comprises fish oil comprising omega-3- and/or omega-6-fatty acid, magnesium and zinc, optionally carriers and further auxiliary materials

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE202007000949U DE202007000949U1 (en) 2007-01-23 2007-01-23 Oral composition, useful for treating e.g. attention deficit disorder, comprises fish oil comprising omega-3- and/or omega-6-fatty acid, magnesium and zinc, optionally carriers and further auxiliary materials

Publications (1)

Publication Number Publication Date
DE202007000949U1 true DE202007000949U1 (en) 2007-04-12

Family

ID=37983157

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202007000949U Expired - Lifetime DE202007000949U1 (en) 2007-01-23 2007-01-23 Oral composition, useful for treating e.g. attention deficit disorder, comprises fish oil comprising omega-3- and/or omega-6-fatty acid, magnesium and zinc, optionally carriers and further auxiliary materials

Country Status (1)

Country Link
DE (1) DE202007000949U1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015879A1 (en) * 2007-07-31 2009-02-05 Fresenius Kabi Deutschland Gmbh Cachexia prevention supplement
EP2130533A1 (en) * 2007-04-05 2009-12-09 J-Oil Mills, Inc. Ataractic agent and functional food
EP2143343A1 (en) * 2008-07-11 2010-01-13 Madeleine Portwood Learning improvement
EP2384648A1 (en) * 2010-05-07 2011-11-09 Deenox SAS New compositions containing omega 3 and usage to treat hangover
WO2012030208A1 (en) * 2010-09-03 2012-03-08 N.V. Nutricia Method and preparation for the treatment or prevention of anxiety or neurogenesis
WO2014174468A3 (en) * 2013-04-23 2014-12-31 Siegfried Rhein S.A. De C.V. Composition of omega-3 fatty acids, zinc and iron for the treatment of attention deficit hyperactivity disorder (adhd)
US20150044138A1 (en) * 2012-03-02 2015-02-12 N.V. Nutricia Method for improving functional synaptic connectivity
CN105192699A (en) * 2015-09-30 2015-12-30 深圳市生命力生物保健科技江苏有限公司 Fish oil soft capsules and preparation method thereof
WO2018176150A1 (en) * 2017-03-29 2018-10-04 Bioflash Inc. Fish egg extracts, omega-3 lipid-based compositions and uses thereof

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2130533A1 (en) * 2007-04-05 2009-12-09 J-Oil Mills, Inc. Ataractic agent and functional food
EP2130533A4 (en) * 2007-04-05 2010-04-21 J Oil Mills Inc Ataractic agent and functional food
US7951844B2 (en) 2007-04-05 2011-05-31 J-Oil Mills, Inc. Tranquilizer and functional food
WO2009015879A1 (en) * 2007-07-31 2009-02-05 Fresenius Kabi Deutschland Gmbh Cachexia prevention supplement
EP2025248A1 (en) * 2007-07-31 2009-02-18 Fresenius Kabi Deutschland GmbH Cachexia prevention supplement
EP2143343A1 (en) * 2008-07-11 2010-01-13 Madeleine Portwood Learning improvement
EP2384648A1 (en) * 2010-05-07 2011-11-09 Deenox SAS New compositions containing omega 3 and usage to treat hangover
WO2012030208A1 (en) * 2010-09-03 2012-03-08 N.V. Nutricia Method and preparation for the treatment or prevention of anxiety or neurogenesis
CN103200830A (en) * 2010-09-03 2013-07-10 N·V·努特里奇亚 Method and preparation for the treatment or prevention of anxiety or neurogenesis
US20150044138A1 (en) * 2012-03-02 2015-02-12 N.V. Nutricia Method for improving functional synaptic connectivity
WO2014174468A3 (en) * 2013-04-23 2014-12-31 Siegfried Rhein S.A. De C.V. Composition of omega-3 fatty acids, zinc and iron for the treatment of attention deficit hyperactivity disorder (adhd)
CN105192699A (en) * 2015-09-30 2015-12-30 深圳市生命力生物保健科技江苏有限公司 Fish oil soft capsules and preparation method thereof
WO2018176150A1 (en) * 2017-03-29 2018-10-04 Bioflash Inc. Fish egg extracts, omega-3 lipid-based compositions and uses thereof
US11439614B2 (en) 2017-03-29 2022-09-13 Bioflash Inc. Fish egg extracts, omega-3 lipid-based compositions and uses thereof

Similar Documents

Publication Publication Date Title
DE202007000949U1 (en) Oral composition, useful for treating e.g. attention deficit disorder, comprises fish oil comprising omega-3- and/or omega-6-fatty acid, magnesium and zinc, optionally carriers and further auxiliary materials
AU2018260866A1 (en) Selective reduction of allelic variants
WO2011097644A3 (en) Selective reduction of allelic variants
DE602008002843D1 (en) NEW ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS
HK1163151A1 (en) Device for cultivating algae and or microorganisms for treating an effluent, and biological frontage
EA201100094A1 (en) TIADIAZOLILOKSIPHENILAMIDINY AND THEIR APPLICATION AS FUNGICIDES
BR112012015501A2 (en) "biodegradation process and composition"
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
PT1913001E (en) (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
PL2162143T3 (en) Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis
BRPI0814941A2 (en) COMPOSITION OF SEED TREATMENT, AND, SEED TREATMENT METHOD.
WO2007109097A3 (en) RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
CL2008003038A1 (en) Compounds derived from spiroheterocyclic pyrrolidine diones; process for the preparation of said compounds; pesticidal composition; method to combat and control pests; and intermediate compounds.
EA200701822A1 (en) PIRAZOLYLKARBOXYANILDS
UA106875C2 (en) Thiadiazolyloxyphenylamidines and Their Applications as Fungicides
EP1945234A4 (en) Composition for preventing or treating artritis comprising lactic acid bacteria and collangen as active ingredients
ATE495676T1 (en) MICROORGANISM AND METHOD FOR PRODUCING L-METHIONINE
PT1968900E (en) Anaerobic purification of wastewater
WO2008101857A3 (en) Coryneform bacteria with formate-thf-synthetase and/or glycine cleavage activity
BRPI0910359A2 (en) method to inhibit the growth of microorganisms and biocidal composition
ATE494384T1 (en) L-CYSTEIN PRODUCING BACTERIA AND METHOD FOR PRODUCING L-CYSTEIN
BRPI0716342A2 (en) '' Composition for controlling the growth of microorganisms, a method for controlling the growth of at least one microorganism and a method for preventing the depletion of a product ''
MX2009006812A (en) Modulators of c3a receptor and methods of use thereof.
WO2008094687A3 (en) Gep, a novel chondrogenic growth factor and target in cartilage disorders
WO2012034118A3 (en) Process for the treatment of biological materials and wastewater

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20070516

R150 Term of protection extended to 6 years

Effective date: 20100113

R082 Change of representative

Representative=s name: BRIDTS NEBL, DE

R081 Change of applicant/patentee

Owner name: KRANICH PHARMA GMBH, DE

Free format text: FORMER OWNER: LUKAS VOGEL,KLAUS WERNER HEUSCHEN,ADAM ALFRED, , DE

Effective date: 20121026

Owner name: KRANICH PHARMA GMBH, DE

Free format text: FORMER OWNERS: VOGEL, LUKAS, DR., 80634 MUENCHEN, DE; HEUSCHEN, KLAUS WERNER, 80639 MUENCHEN, DE; ALFRED, ADAM, DR., 80639 MUENCHEN, DE

Effective date: 20121026

R082 Change of representative

Representative=s name: BRIDTS NEBL, DE

Effective date: 20121026

Representative=s name: VOSSIUS & PARTNER, DE

Effective date: 20121026

Representative=s name: VOSSIUS & PARTNER PATENTANWAELTE RECHTSANWAELT, DE

Effective date: 20121026

R082 Change of representative

Representative=s name: VOSSIUS & PARTNER, DE

Representative=s name: VOSSIUS & PARTNER PATENTANWAELTE RECHTSANWAELT, DE

R151 Term of protection extended to 8 years

Effective date: 20130123

R152 Term of protection extended to 10 years
R152 Term of protection extended to 10 years

Effective date: 20141201

R071 Expiry of right